CNS Regenerative Focus Convelo targets myelin regeneration in MS and leukodystrophies, with two oral candidates in preclinical stages. This creates demand for discovery and preclinical services, such as GLP toxicology, pharmacokinetics, drug formulation, and GMP-grade CMC materials, as well as biomarker and imaging support to de-risk early development.

Strategic Partnerships Potential Past collaboration with Genentech signals openness to co-development with large pharma; seek expansion partnerships or licensing deals with neurodegenerative franchises, enabling access to capital, manufacturing, and late-stage development capabilities.

Early Stage Funding Readiness With modest team size and early funding, Convelo could accelerate partnerships that provide non-dilutive funding, grant support, or strategic investments while they mature their pipeline.

Regulatory Readiness As they advance, there is demand for IND-enabling studies, regulatory strategy, and clinical operations planning; BD opportunities to offer or partner on regulatory consulting, trial design, and vendor management.

Market Positioning Access Unique focus on myelin repair places Convelo in a niche with MS, leukodystrophies, and CNS injury; opportunities to assist with market access, payer value propositions, and patient advocacy partnerships to accelerate adoption.